OPENING OF BANKRUPTCY

Mithra Pharmaceuticals

Export PDF

Company — Opening of bankruptcy.

Financial year 2022 · Closed on 31/12/2022

Net result-42,5 M €-4 713,3 %over 1 year

Revenue23,3 M €+48,5 %over 1 year

Equity290,2 M €+16,1 %over 1 year

Workforce40,0 ETP-2,4 %over 1 year

Identity

Source · BCE/KBO

Mithra Pharmaceuticals is a Public limited company incorporated in 1999. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Liège. It employs on average 40,0 ETP workers (FTE).

Legal situation: Opening of bankruptcy
BCE/KBO no. / VAT: BE 0466.526.646
Incorporation: 13/07/1999
Legal form: Public limited company
Registered office: Rue Saint-Georges 5
4000 Liège · WallonieSee on map
Contributed capital: 453 738 055,00 €
Latest accounts: 31/12/2022
Average workforce: 40,0 ETP

Activities (NACE)

21201Manufacture of pharmaceutical preparations· main 21201Manufacture of pharmaceutical preparations 24421Aluminium production 46499Wholesale of other household goods 46499Wholesale of other household goods 51478Air transport

Joint committees (1)

Signals

Solid equityGood liquidityPositive EBITDAHealthy social debtsHigh revenue

Financials

Source · NBB, 26 filings

Trend over 15 financial years

	2022		2021		2020		2019		2018
Income statement
Revenue	23,3 M €	+48.5%	15,7 M €	-6.0%	16,7 M €	+30.0%	12,8 M €	-74.2%	49,8 M €
EBITDA	94 k €	-96.1%	2,4 M €	+77.9%	1,4 M €	+102%	668,8 k €	+106%	-11,1 M €
Operating result	-438,9 k €	-124%	1,8 M €	+71.2%	1,1 M €	+135%	449,9 k €	+103%	-15 M €
Net result	-42,5 M €	-4713%	-883,8 k €	+95.9%	-21,3 M €	+38.7%	-34,7 M €	-141%	-14,4 M €
Balance sheet
Equity	290,2 M €	+16.1%	249,9 M €	+3.5%	241,5 M €	+24.0%	194,7 M €	+2.3%	190,4 M €
Total assets	513,6 M €	+11.6%	460,1 M €	+3.1%	446,1 M €	+76.5%	252,7 M €	-2.8%	260 M €
Cash	27,6 M €	+61.9%	17 M €	-86.2%	123,1 M €	+198%	41,2 M €	-64.8%	117,2 M €
Debts	221 M €	+5.4%	209,7 M €	+2.8%	203,9 M €	+254%	57,6 M €	-16.9%	69,3 M €
Other
Workforce	40,0 ETP	-2.4%	41,0 ETP	0.0%	41,0 ETP	-18.0%	50,0 ETP	-9.1%	55,0 ETP

Board of directors

Source · NBB, accounts to 31/12/2022

11 active · 84 ended

Active mandates

ALIUS MODI

Director · since 20 mai 2021 · until 25 mai 2023 · 0809.631.185

Represented by Valérie Gordenne

Active

AMEL TOUNSI

Director · since 20 mai 2021 · until 25 mai 2023

Active

An Cloet

Director · since 20 mai 2021 · until 25 mai 2023

Active

EVACONSULTING

Director · since 20 mai 2021 · until 25 mai 2023 · 0874.027.804

Represented by Jean Michel Foidart

Active

Liesbeth Weynants

Director · since 20 mai 2021 · until 25 mai 2023

Active

NOSHAQ

Director · since 20 mai 2021 · until 25 mai 2023 · 0426.624.509

Represented by Gaetan Servais

Active

SUNATHIM

Director · since 20 mai 2021 · until 06 juillet 2022 · 0474.893.093

Represented by Ajit Shetty

Active

TICACONSULT

Director · since 20 mai 2021 · until 25 mai 2023 · 0636.809.156

Represented by Erik Van den Eynden

Active

YIMA

Director · since 20 mai 2021 · until 18 juin 2022 · 0871.523.818

Represented by François Fornieri

Active

Patricia Van Dijck

Director · since 16 mai 2019 · until 25 mai 2023

Active

SELVA LUXEMBOURG SA

Director · since 16 mai 2019 · until 25 mai 2023

Represented by Christian Moretti

Active

Ended mandates

ALIUS MODI

Director · since 20 mai 2021 · until 18 mai 2023 · 0809.631.185

Represented by Valérie Gordenne

Ended

AMEL TOUNSI

Director · since 20 mai 2021 · until 18 mai 2023

Ended

An Cloet

Director · since 20 mai 2021 · until 18 mai 2023

Ended

EVACONSULTING

Director · since 20 mai 2021 · until 18 mai 2023 · 0874.027.804

Represented by Jean Michel Foidart

Ended

Other companies at this address

Rue Saint-Georges 5 4000 Liège

Company	CBE no.
ESTETRA● Active	0818.257.356
MITHRA PHARMACEUTICALS CDMO● Bankrupt	0534.912.933
MITHRA Recherche et Développement● Bankrupt	0534.909.666
NOVALON● Bankrupt	0877.126.557
UTERON PHARMA PARTICIPATIONS I● Active	0736.403.907

Full financial information

Source · NBB

	2022	2021	2020	2019	2018	2017
Type of account	Full model	Full model	Full model	Full model	Full model	Consolidated accounts
Start of the financial year	01/01/2022	01/01/2021	01/01/2020	01/01/2019	01/01/2018	01/01/2017
Closing of the financial year	31/12/2022	31/12/2021	31/12/2020	31/12/2019	31/12/2018	31/12/2017
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	12/06/2023	24/06/2022	15/06/2021	30/06/2020	15/04/2020	01/06/2018
General meeting	25/05/2023	19/05/2022	20/05/2021	21/05/2020	16/05/2019	17/05/2018
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 26 filings

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2022	25/05/2023	12/06/2023	French	PDF
Consolidated accounts	31/12/2022	25/05/2023	13/06/2023	French	PDF
Full model	31/12/2021	19/05/2022	24/06/2022	French	PDF
Consolidated accounts	31/12/2021	19/05/2022	24/06/2022	French	PDF
Full model	31/12/2020	20/05/2021	15/06/2021	French	PDF
Consolidated accounts	31/12/2020	20/05/2021	15/06/2021	French	PDF
Full model	31/12/2019	21/05/2020	30/06/2020	French	PDF
Consolidated accounts	31/12/2019	21/05/2020	30/06/2020	French	PDF
Full modelCorrection	31/12/2018	16/05/2019	15/04/2020	French	PDF
Full model	31/12/2018	16/05/2019	21/06/2019	French	PDF
Consolidated accounts	31/12/2018	16/05/2019	24/06/2019	French	PDF
Full model	31/12/2017	17/05/2018	30/05/2018	French	PDF
Consolidated accounts	31/12/2017	17/05/2018	01/06/2018	French	PDF
Full model	31/12/2016	18/05/2017	16/06/2017	French	PDF
Consolidated accounts	31/12/2016	18/05/2017	16/06/2017	French	PDF
Full model	31/12/2015	19/05/2016	04/08/2016	French	PDF
Consolidated accounts	31/12/2015	19/05/2016	21/12/2016	French	PDF
Full model	31/12/2014	21/05/2015	04/06/2015	French	PDF
Full model	31/12/2013	04/08/2014	07/08/2014	French	PDF
Full model	31/12/2012	28/06/2013	08/07/2013	French	PDF
Full model	31/12/2011	24/05/2012	04/06/2012	French	PDF
Full model	31/12/2010	07/06/2011	11/07/2011	French	PDF
Full model	31/12/2009	28/06/2010	26/07/2010	French	PDF
Full model	31/12/2008	22/05/2009	25/05/2009	French	PDF

View all 26 filings

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2022

11 active · 84 ended

Active mandates

ALIUS MODI

Director · since 20 mai 2021 · until 25 mai 2023 · 0809.631.185

Represented by Valérie Gordenne

Active

AMEL TOUNSI

Director · since 20 mai 2021 · until 25 mai 2023

Active

An Cloet

Director · since 20 mai 2021 · until 25 mai 2023

Active

EVACONSULTING

Director · since 20 mai 2021 · until 25 mai 2023 · 0874.027.804

Represented by Jean Michel Foidart

Active

Liesbeth Weynants

Director · since 20 mai 2021 · until 25 mai 2023

Active

NOSHAQ

Director · since 20 mai 2021 · until 25 mai 2023 · 0426.624.509

Represented by Gaetan Servais

Active

SUNATHIM

Director · since 20 mai 2021 · until 06 juillet 2022 · 0474.893.093

Represented by Ajit Shetty

Active

TICACONSULT

Director · since 20 mai 2021 · until 25 mai 2023 · 0636.809.156

Represented by Erik Van den Eynden

Active

YIMA

Director · since 20 mai 2021 · until 18 juin 2022 · 0871.523.818

Represented by François Fornieri

Active

Patricia Van Dijck

Director · since 16 mai 2019 · until 25 mai 2023

Active

SELVA LUXEMBOURG SA

Director · since 16 mai 2019 · until 25 mai 2023

Represented by Christian Moretti

Active

Ended mandates

ALIUS MODI

Director · since 20 mai 2021 · until 18 mai 2023 · 0809.631.185

Represented by Valérie Gordenne

Ended

AMEL TOUNSI

Director · since 20 mai 2021 · until 18 mai 2023

Ended

An Cloet

Director · since 20 mai 2021 · until 18 mai 2023

Ended

EVACONSULTING

Director · since 20 mai 2021 · until 18 mai 2023 · 0874.027.804

Represented by Jean Michel Foidart

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates10/04/2024
DEMISSIONS, NOMINATIONS
PDF
Capital / shares22/12/2023
CAPITAL, ACTIONS
PDF
Mandates07/12/2023
DEMISSIONS, NOMINATIONS
PDF
Mandates07/12/2023
DEMISSIONS, NOMINATIONS
PDF
Other28/11/2023
STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
PDF
Capital / shares20/09/2023
CAPITAL, ACTIONS
PDF
Capital / shares30/08/2023
CAPITAL, ACTIONS
PDF
Mandates28/06/2023
DEMISSIONS, NOMINATIONS
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

05/03/2024
nominationC2M4E Srl — administrateur
04/03/2024
nominationCMM&C SRL — co-CEO / co-délégué à la gestion journalière
04/03/2024
nominationXavier Paoli — co-CEO / co-délégué à la gestion journalière
21/09/2023
nominationInge Beernaert BV — administratrice
21/09/2023
nominationSRL Bronzet Management — délégué à la gestion journalière
18/09/2023
augmentation_capital
23/06/2023
augmentation_capital
25/05/2023
augmentation_capital
11/05/2023
augmentation_capital
11/04/2023
nominationDavid H. Solomon — délégué à la gestion journalière (CEO)
13/03/2023
augmentation_capital
13/02/2023
augmentation_capital
2022
Annual accounts 2022-42,5 M €↓
30/12/2022
augmentation_capital
21/12/2022
augmentation_capital
06/12/2022
augmentation_capital
02/12/2022
augmentation_capital
21/11/2022
augmentation_capital
17/11/2022
augmentation_capital
31/10/2022
augmentation_capital
18/10/2022
augmentation_capital
26/09/2022
augmentation_capital
22/09/2022
augmentation_capital
14/09/2022
augmentation_capital
05/09/2022
augmentation_capital
29/08/2022
augmentation_capital
22/08/2022
augmentation_capital
17/08/2022
augmentation_capital
10/08/2022
augmentation_capital
05/07/2022
nominationMoretti — Président du Conseil d'administration
05/07/2022
nominationVan Den Eynden — Vice-Président
24/06/2022
augmentation_capital
31/05/2022
augmentation_capital
19/04/2022
augmentation_capital
14/02/2022
augmentation_capital
2021
Annual accounts 2021-883,8 k €↑
2020
Annual accounts 2020-21,3 M €↑
2019
Annual accounts 2019-34,7 M €↓
2018
Annual accounts 2018-14,4 M €↑
2016
Annual accounts 2016-14,5 M €↓
2014
Annual accounts 201410 k €↓
2013
Annual accounts 2013976,3 k €↑
2012
Annual accounts 2012586,7 k €↓
2011
Annual accounts 20111,9 M €↓
2010
Annual accounts 20105 M €↑
2009
Annual accounts 2009-1,6 M €↓
2008
Annual accounts 2008578,6 k €↑
2007
Annual accounts 2007391 k €↑
2006
Annual accounts 2006311,7 k €
13/07/1999
IncorporationPublic limited company

Mithra Pharmaceuticals

Overview

Identity

Financials

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline